Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

被引：0
|
作者：
Marit A. C. Vermunt
Merel van Nuland
Lisa T. van der Heijden
Hilde Rosing
Jos. H. Beijnen
Andries M. Bergman
机构：
[1] The Netherlands Cancer Institute,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Department of Medical Oncology
[3] Utrecht University,Department of Pharmaceutical Sciences
[4] Modra Pharmaceuticals B.V.,Department of Oncogenomics
[5] The Netherlands Cancer Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
Docetaxel; Pharmacokinetics; Metastatic castration-resistant prostate cancer; Metastatic hormone-sensitive prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：785 / 793
页数：8
相关论文
共 50 条
  • [21] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Identifying Patients With Rapid Progression From Hormone-Sensitive to Castration-Resistant Prostate Cancer: A Retrospective Study
    Pan, Chenxi
    He, Yi
    Wang, He
    Yu, Yang
    Li, Lu
    Huang, Lingling
    Lyu, Mengge
    Ge, Weigang
    Yang, Bo
    Sun, Yaoting
    Guo, Tiannan
    Liu, Zhiyu
    MOLECULAR & CELLULAR PROTEOMICS, 2023, 22 (09) : 100613
  • [23] Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer
    Liu, Yufei
    Jiang, Haowen
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (05) : 1937 - 1944
  • [24] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [25] SBRT for oligometastatic lymph nodes in hormone-sensitive and castration-resistant prostate cancer.
    Giaj-Levra, N.
    Fersino, S.
    Fiorentino, A.
    Tebano, U.
    Aiello, D.
    Mazzola, R.
    Ricchetti, F.
    Ruggieri, R.
    Salgarello, M.
    Alongi, F.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S832 - S832
  • [26] Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
    Wenzel, Mike
    Hoeh, Benedikt
    Kopf, Philipp
    Siech, Carolin
    Humke, Clara
    Wurnschimmel, Christoph
    Steuber, Thomas
    Graefen, Markus
    Preisser, Felix
    Traumann, Miriam
    Banek, Severine
    Kluth, Luis A.
    Chun, Felix KH.
    Mandel, Philipp
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (11) : 371e11 - 371e18
  • [27] Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients
    Wenzel, Mike
    Siech, Carolin
    Hoeh, Benedikt
    Koll, Florestan
    Humke, Clara
    Tilki, Derya
    Steuber, Thomas
    Graefen, Markus
    Banek, Severine
    Kluth, Luis A.
    Chun, Felix K. H.
    Mandel, Philipp
    EUROPEAN UROLOGY OPEN SCIENCE, 2024, 66 : 46 - 54
  • [28] Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients
    Poon, Darren M. C.
    Chan, Kuen
    Chan, Tim-Wai
    Ng, Bryan
    Siu, Steven
    Ng, Joyce
    Johnson, David
    Lee, Ka Chai
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 39 - 47
  • [29] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
  • [30] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
12345